secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001171843-25-001183
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Cassava Sciences Reports 2024 Financial Results and Provides Business Update
----------------------------------------------------------------------------

- Net loss of $24.3 million ($0.53 per share) in 2024 vs $97.2 million in 2023; cash and equivalents $128.6 million with no debt.
- Top-line data for REFOCUS-ALZ, second Phase 3 study of simufilam in Alzheimer's, expected late Q1/early Q2 2025.
- RETHINK-ALZ Phase 3 study did not meet co-primary endpoints in November 2024; all Alzheimer's clinical studies discontinued.
- License agreement with Yale University to explore simufilam for seizures related to tuberous sclerosis complex (TSC).
- G&A expenses rose to $71.8 million in 2024 due to $40 million SEC settlement and higher stock-based compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184325001183/0001171843-25-001183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184325001183/f8k_030325.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer